The role of fungal proteinases in pathophysiology of Stachybotrys chartarum.
The adverse health effects of Stachybotrys chartarum have often been linked to exposure to the trichothecene mycotoxins. Recent studies have shown that in addition to mycotoxins this fungus is capable of producing and secreting in vivo proteins such as hemolysins and proteinases. Spore extracts obtained from a high trichothecene producing isolate JS 58-17 exhibited a significantly lower proteolytic activity compared to the low trichothecene producer, JS 58-06. Growing isolates on rice or potato dextrose agar results in higher proteolytic activity of the spores compared to those grown on drywall. Proteinases in the spore extracts can hydrolyze gelatin and collagen I and IV. Analysis of zymograms shows the presence of several proteins with proteolytic activity in the spores of S. chartarum. Human tracheal epithelial cells exposed to spore extracts produced significantly higher levels of IL-6, IL-8, and TNF-alpha than control cells. This stimulation of cytokine production was completely abolished by Pefabloc, a serine protease inhibitor. Neutrophil numbers and proinflammatory cytokine (IL1-beta and TNF-alpha) concentrations were highly elevated in the lungs of 7 day old rat pups exposed intratracheally to 4 x 10(4) spores/gm body weight compared to control. No significant differences in those inflammatory indices in vivo were noted between the treatments with the high trichothecene producer, isolate JS 58-17 and JS 58-06, which does not produce macrocyclic trichothecenes. Immunohistochemistry revealed reduced collagen IV labeling in spore-induced lung granulomas in rat pups exposed to both isolates. These results suggest that proteinases from S. chartarum spores significantly contribute to lung inflammation and injury.
Yike
Iwona
I
Mary Ann Swetland Center for Environmental Health, Case Western Reserve University, Cleveland, OH 44106, USA. ixy@case.edu
Rand
Thomas
T
Dearborn
Dorr G
DG
D000818:Animals; D000831:Animals, Newborn; D002461:Cell Line, Transformed; D024141:Collagen Type IV / Q000378:metabolism; D003470:Culture Media / Q000737:chemistry / Q000494:pharmacology; D016207:Cytokines / Q000378:metabolism; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D005260:Female; D005656:Fungal Proteins / Q000378:metabolism / Q000502:physiology*; D005780:Gelatin / Q000378:metabolism; D006099:Granuloma / Q000378:metabolism / Q000382:microbiology / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008172:Lung Diseases, Fungal / Q000378:metabolism / Q000473:pathology; D008954:Models, Biological; D010447:Peptide Hydrolases / Q000378:metabolism*; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology; D013172:Spores, Fungal / Q000737:chemistry / Q000201:enzymology / Q000472:pathogenicity; D013191:Stachybotrys / Q000737:chemistry / Q000201:enzymology* / Q000472:pathogenicity; D013450:Sulfones / Q000494:pharmacology; D014132:Trachea / Q000166:cytology
D024141:Collagen Type IV; D003470:Culture Media; D016207:Cytokines; D005656:Fungal Proteins; D015842:Serine Proteinase Inhibitors; D013450:Sulfones; C002010:4-(2-aminoethyl)benzenesulfonylfluoride; D005780:Gelatin; D010447:Peptide Hydrolases